April 24th 2024
Both the SOLAR-STAGE and SOLAR-RECUR trials are currently enrolling patients with prostate cancer in the US, with additional sites expected to open in Europe later this year.
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
How the Experts Treat NMIBC During a BCG Shortage—Integrating Recent Approvals and Investigational Therapies
View More
Staying Abreast of the Prostate Cancer Treatment Paradigm From Risk Stratification to Adaptive Sequencing Strategies
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Medical Crossfire®: How Will Emerging Data Inform Treatment Planning for Patients With Prostate Cancer in the Community?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Dr. Kuo on PSMA-PET imaging biomarker research
June 21st 2022Phillip Kuo, MD, PhD, discusses the abstract, “[68Ga]Ga-PSMA-11 PET baseline imaging as a prognostic tool for clinical outcomes to [177Lu]Lu-PSMA-617 in patients with mCRPC: A VISION substudy,” which was presented at the 2022 ASCO Annual Meeting.
Reader reproducibility high with 18F-rhPSMA-7.3 image interpretation in prostate cancer
June 15th 2022“These findings from the SPOTLIGHT study showed high inter-reader and intra-reader agreement for interpretation of 18F-rhPSMA-7.3 PET/CT scans in the setting of biochemical recurrence,” said Phillip Kuo, MD, PhD.
Dr. Tagawa on 2 radiopharmaceuticals for prostate cancer with a proven survival advantage
April 18th 2022“Overall, there's no known advantage or disadvantage in a head-to-head trial of either one of these, but I do think they're complementary,” says Scott T. Tagawa, MD, when discussing radium-223 dichloride and lutetium Lu 177 vipivotide tetraxetan.
Expert explains significance of FDA approval of 177Lu-PSMA-617 for mCRPC
April 11th 2022Richard Wahl, MD, president of the Society of Nuclear Medicine and Molecular Imaging, highlights the approval of 177Lu-PSMA-617 (Lu 177 vipivotide tetraxetan) as the first targeted radioligand therapy for the treatment of progressive, PSMA-positive metastatic castration-resistant prostate cancer.
Study launches of Cu-64 SAR-bisPSMA in biochemically recurrent prostate cancer
April 1st 2022Eligible patients for the multicenter, nonrandomized, single-arm trial (NCT05249127) will have suspected recurrence of prostate cancer as determined by a rising prostate-specific antigen following definitive therapy.